Recombinant Llama Anti-BMP4 Single Domain Antibody (HPAB-0357-YC-VHH) (CAT#: HPAB-0357-YC-VHH)

Figure 1 VHH specificity compared to different inhibitors.

C2C12 cells were activated with 10 ng/ml of hBMP4. At the same time the inhibitors were added.

Calpe, S., Correia, A. C., Sancho-Serra, M. D. C., & Krishnadath, K. K. (2016, May). Comparison of newly developed anti-bone morphogenetic protein 4 llama-derived antibodies with commercially available BMP4 inhibitors. In Mabs (Vol. 8, No. 4, pp. 678-688). Taylor & Francis.

Figure 2 VHH efficacy compared to different available inhibitors.

C2C12 cells were stimulated with 50 ng/ml of BMP2, and at the same time increasing concentrations of anti-BMP4 antibodies and VHHs were added (0.1 g/ml to 5 g/ml).

Calpe, S., Correia, A. C., Sancho-Serra, M. D. C., & Krishnadath, K. K. (2016, May). Comparison of newly developed anti-bone morphogenetic protein 4 llama-derived antibodies with commercially available BMP4 inhibitors. In Mabs (Vol. 8, No. 4, pp. 678-688). Taylor & Francis.

Figure 3 VHH efficacy compared to different available inhibitors.

IC50 curves of the inhibition of BMP4-mediated signals by VHHs, commercial anti-BMP4 antibodies and natural antagonists.

Calpe, S., Correia, A. C., Sancho-Serra, M. D. C., & Krishnadath, K. K. (2016, May). Comparison of newly developed anti-bone morphogenetic protein 4 llama-derived antibodies with commercially available BMP4 inhibitors. In Mabs (Vol. 8, No. 4, pp. 678-688). Taylor & Francis.

Figure 4 Epitope mapping with hBMP4.

Comparison of BMP4 binding sites between antibodies. C2C12 cells were stimulated with 10 ng/ml of BMP4 or 1,000 ng/ml of hBMP4. At the same time the antibodies were added at a concentration of 10 g/ml.

Calpe, S., Correia, A. C., Sancho-Serra, M. D. C., & Krishnadath, K. K. (2016, May). Comparison of newly developed anti-bone morphogenetic protein 4 llama-derived antibodies with commercially available BMP4 inhibitors. In Mabs (Vol. 8, No. 4, pp. 678-688). Taylor & Francis.

Figure 5 Kinetic analysis for BMP binding.

Binding of VHHs to the different BMPs was tested in a direct SPR assay. The graphs show two replicate ligand injections at just one concentration of ligand.

Calpe, S., Wagner, K., El Khattabi, M., Rutten, L., Zimberlin, C., Dolk, E., ... & Krishnadath, K. K. (2015). Effective inhibition of bone morphogenetic protein function by highly specific llama-derived antibodies. Molecular cancer therapeutics, 14(11), 2527-2540.

Figure 6 Kinetic analysis for BMP binding.

Epitope binning of VHH-coated chip plates. BMP4 (1.0 mg/mL) was injected on the chip followed by the injection of a second VHH (2.0 mg/mL) or the corresponding controls.

Calpe, S., Wagner, K., El Khattabi, M., Rutten, L., Zimberlin, C., Dolk, E., ... & Krishnadath, K. K. (2015). Effective inhibition of bone morphogenetic protein function by highly specific llama-derived antibodies. Molecular cancer therapeutics, 14(11), 2527-2540.

Figure 7 VHH biheads inhibit endogenous BMP function.

BMP activity of conditioned media of organoids cultured at the indicated conditions for 3 days.

Calpe, S., Wagner, K., El Khattabi, M., Rutten, L., Zimberlin, C., Dolk, E., ... & Krishnadath, K. K. (2015). Effective inhibition of bone morphogenetic protein function by highly specific llama-derived antibodies. Molecular cancer therapeutics, 14(11), 2527-2540.

Figure 8 VHH biheads inhibit endogenous BMP function.

Number of organoids formed in cultures of mouse intestinal organoids grown for 5 days at the indicated conditions.

Calpe, S., Wagner, K., El Khattabi, M., Rutten, L., Zimberlin, C., Dolk, E., ... & Krishnadath, K. K. (2015). Effective inhibition of bone morphogenetic protein function by highly specific llama-derived antibodies. Molecular cancer therapeutics, 14(11), 2527-2540.

Figure 9 Anti-BMP4 VHHs inhibit cancer-derived BMP signals.

C2C12 cells were incubated with conditioned media of the indicated cancer cell lines. C4C4, C8C8, or human Fc-Noggin were added at the same time at a concentration of 500 ng/mL for 16 hours.

Calpe, S., Wagner, K., El Khattabi, M., Rutten, L., Zimberlin, C., Dolk, E., ... & Krishnadath, K. K. (2015). Effective inhibition of bone morphogenetic protein function by highly specific llama-derived antibodies. Molecular cancer therapeutics, 14(11), 2527-2540.